• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    52 Weeks High And Low Article

    3/2/22 10:33:51 AM ET
    $ADAP
    $ADV
    $AGLE
    $AKA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ADAP alert in real time by email

     

     

    Wednesday's session saw 107 companies set new 52-week lows.

    Points of Interest From Today's 52-Week Lows:

    • Citigroup (NYSE:C) was the largest company by market cap to set a new 52-week low.
    • Mobiquity Technologies (NASDAQ:MOBQ) was the smallest company by market cap to set a new 52-week low.
    • SAB Biotherapeutics (NASDAQ:SABS)'s stock came under the most pressure, trading down 52.51% to reach a new 52-week low.
    • Neenah (NYSE:NP)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low.

    Over the course of trading on Wednesday, the following stocks hit new 52-week lows:

    • Citigroup (NYSE:C) shares reached a new 52-week low of $55.93 on Wednesday morning, moving down 4.46%.
    • Dr Reddy's Laboratories (NYSE:RDY) shares set a new 52-week low of $50.15. The stock traded down 2.58%.
    • HashiCorp (NASDAQ:HCP) shares moved down 6.63% on Wednesday to hit a new 52-week low of $44.50, drifting down 6.63%.
    • GoodRx Holdings (NASDAQ:GDRX) shares made a new 52-week low of $15.82 on Wednesday. The stock was down 4.66% for the day.
    • Weibo (NASDAQ:WB) stock dropped to a yearly low on Wednesday of $26.62. Shares traded down 0.61%.
    • Ardagh Metal Packaging (NYSE:AMBP) stock broke to a new 52-week low of $7.72 on Wednesday. Shares of the company traded up 0.58%.
    • Certara (NASDAQ:CERT) stock set a new 52-week low of $20.51 on Wednesday, moving down 10.1%.
    • Duolingo (NASDAQ:DUOL) shares fell to $77.59 on Wednesday, setting a new 52-week low with a shift of down 5.2%.
    • Kyndryl Hldgs (NYSE:KD) stock dropped to a yearly low on Wednesday of $12.88. Shares traded down 3.33%.
    • Bumble (NASDAQ:BMBL) stock hit a yearly low of $22.08. The stock was down 3.34% for the day.
    • Diversey Holdings (NASDAQ:DSEY) shares fell to $8.83 on Wednesday, setting a new 52-week low with a shift of down 4.19%.
    • United Breweries Co (NYSE:CCU) shares set a new yearly low of $14.79 this morning. The stock was down 0.6% on the session.
    • BRF (NYSE:BRFS) shares made a new 52-week low of $3.07 on Wednesday. The stock was down 1.67% for the day.
    • PTC Therapeutics (NASDAQ:PTCT) stock hit a yearly low of $33.82. The stock was down 0.47% for the day.
    • Advantage Solutions (NASDAQ:ADV) shares moved down 10.38% on Wednesday to hit a new 52-week low of $6.09, drifting down 10.38%.
    • Enel Chile (NYSE:ENIC) shares reached a new 52-week low of $1.54 on Wednesday morning, moving down 3.7%.
    • Manchester United (NYSE:MANU) shares moved up 0.31% on Wednesday to hit a new 52-week low of $12.74, drifting up 0.31%.
    • Qurate Retail (NASDAQ:QRTEB) stock hit a yearly low of $5.44. The stock was down 9.33% for the day.
    • Noah Holdings (NYSE:NOAH) shares moved down 4.4% on Wednesday to hit a new 52-week low of $25.62, drifting down 4.4%.
    • Dave (NASDAQ:DAVE) stock hit a yearly low of $4.09. The stock was down 3.95% for the day.
    • Allbirds (NASDAQ:BIRD) shares fell to $7.01 on Wednesday, setting a new 52-week low with a shift of down 7.88%.
    • Shenandoah (NASDAQ:SHEN) shares set a new 52-week low of $19.74. The stock traded up 1.01%.
    • American Well (NYSE:AMWL) shares were down 5.5% for the day, having made a 52-week low of $3.67.
    • Butterfly Network (NYSE:BFLY) shares set a new yearly low of $4.56 this morning. The stock was down 5.32% on the session.
    • ATRenew (NYSE:RERE) shares set a new yearly low of $3.94 this morning. The stock was down 2.64% on the session.
    • Atara Biotherapeutics (NASDAQ:ATRA) shares were down 3.04% for the day, having made a 52-week low of $9.63.
    • Science 37 Hldgs (NASDAQ:SNCE) shares were down 2.17% for the day, having made a 52-week low of $7.20.
    • Hydrofarm Holdings Group (NASDAQ:HYFM) shares set a new yearly low of $16.56 this morning. The stock was down 11.02% on the session.
    • a.k.a. Brands Holding (NYSE:AKA) shares set a new 52-week low of $5.07. The stock traded down 24.5%.
    • ZimVie (NASDAQ:ZIMV) stock hit a new 52-week low of $24.50. The stock was up 0.04% on the session.
    • Diebold Nixdorf (NYSE:DBD) stock set a new 52-week low of $7.53 on Wednesday, moving up 0.38%.
    • Neenah (NYSE:NP) shares fell to $35.48 on Wednesday, setting a new 52-week low with a shift of 0.0% (flat).
    • Groupon (NASDAQ:GRPN) shares set a new yearly low of $18.97 this morning. The stock was down 3.64% on the session.
    • Loyalty Ventures (NASDAQ:LYLT) shares set a new yearly low of $21.74 this morning. The stock was down 1.04% on the session.
    • Vital Farms (NASDAQ:VITL) stock broke to a new 52-week low of $13.03 on Wednesday. Shares of the company traded down 2.76%.
    • IDEAYA Biosciences (NASDAQ:IDYA) stock broke to a new 52-week low of $12.62 on Wednesday. Shares of the company traded up 0.08%.
    • Vroom (NASDAQ:VRM) shares hit a yearly low of $3.03. The stock was down 2.62% on the session.
    • Kodiak Sciences (NASDAQ:KOD) shares fell to $8.19 on Wednesday, setting a new 52-week low with a shift of down 6.22%.
    • Purple Innovation (NASDAQ:PRPL) shares set a new 52-week low of $5.05. The stock traded up 10.73%.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares made a new 52-week low of $2.28 on Wednesday. The stock was down 2.49% for the day.
    • ATI Physical Therapy (NYSE:ATIP) stock hit a yearly low of $1.73. The stock was down 5.29% for the day.
    • Morgan Stanley Emerging (NYSE:EDD) shares reached a new 52-week low of $5.07 on Wednesday morning, moving down 0.39%.
    • Semler Scientific (NASDAQ:SMLR) stock hit $49.72 on Wednesday morning, setting a new 52-week low for a change of down 5.55%.
    • Templeton Emerging Market (NYSE:TEI) stock hit $6.71 on Wednesday morning, setting a new 52-week low for a change of up 0.11%.
    • 1stdibs.com (NASDAQ:DIBS) shares set a new yearly low of $6.49 this morning. The stock was down 23.18% on the session.
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) stock dropped to a yearly low on Wednesday of $2.00. Shares traded down 4.5%.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) shares were down 1.56% for the day, having made a 52-week low of $7.51.
    • Oyster Point Pharma (NASDAQ:OYST) shares fell to $8.57 on Wednesday, setting a new 52-week low with a shift of down 4.71%.
    • Romeo Power (NYSE:RMO) stock set a new 52-week low of $1.50 on Wednesday, moving down 10.0%.
    • Hemisphere Media (NASDAQ:HMTV) stock set a new 52-week low of $4.96 on Wednesday, moving up 1.4%.
    • Zevia (NYSE:ZVIA) stock dropped to a yearly low on Wednesday of $5.68. Shares traded down 4.23%.
    • Annexon (NASDAQ:ANNX) shares reached a new 52-week low of $4.56 on Wednesday morning, moving down 2.75%.
    • Cue Biopharma (NASDAQ:CUE) stock set a new 52-week low of $5.28 on Wednesday, moving down 5.03%.
    • Cyteir Therapeutics (NASDAQ:CYT) stock set a new 52-week low of $4.58 on Wednesday, moving down 5.07%.
    • Werewolf Therapeutics (NASDAQ:HOWL) shares reached a new 52-week low of $5.70 on Wednesday morning, moving down 2.57%.
    • Pyxis Oncology (NASDAQ:PYXS) shares set a new yearly low of $4.75 this morning. The stock was down 5.83% on the session.
    • Fortress Biotech (NASDAQ:FBIO) stock drifted down 7.23% on Wednesday morning to hit a new 52-week low of $1.52.
    • GoHealth (NASDAQ:GOCO) shares reached a new 52-week low of $1.21 on Wednesday morning, moving down 34.67%.
    • Synchronoss Technologies (NASDAQ:SNCR) shares made a new 52-week low of $1.51 on Wednesday. The stock was down 0.33% for the day.
    • Jasper Therapeutics (NASDAQ:JSPR) shares fell to $3.31 on Wednesday, setting a new 52-week low with a shift of down 2.29%.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares moved down 1.87% on Wednesday to hit a new 52-week low of $2.52, drifting down 1.87%.
    • Tuesday Morning (NASDAQ:TUEM) shares moved down 0.72% on Wednesday to hit a new 52-week low of $1.36, drifting down 0.72%.
    • Sonendo (NYSE:SONX) shares moved down 6.08% on Wednesday to hit a new 52-week low of $4.32, drifting down 6.08%.
    • Exagen (NASDAQ:XGN) shares moved down 1.12% on Wednesday to hit a new 52-week low of $7.04, drifting down 1.12%.
    • Esports Technologies (NASDAQ:EBET) stock dropped to a yearly low on Wednesday of $7.16. Shares traded up 4.75%.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock set a new 52-week low of $2.82 on Wednesday, moving down 4.61%.
    • Sensei Biotherapeutics (NASDAQ:SNSE) shares moved down 3.97% on Wednesday to hit a new 52-week low of $3.30, drifting down 3.97%.
    • Frequency Therapeutics (NASDAQ:FREQ) shares set a new yearly low of $2.71 this morning. The stock was up 0.73% on the session.
    • SAB Biotherapeutics (NASDAQ:SABS) shares moved down 52.51% on Wednesday to hit a new 52-week low of $2.15, drifting down 52.51%.
    • Zedge (AMEX:ZDGE) stock hit $5.76 on Wednesday morning, setting a new 52-week low for a change of down 8.23%.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock hit a yearly low of $2.05. The stock was down 4.63% for the day.
    • First Trust/aberdeen Glb (NYSE:FAM) stock hit a new 52-week low of $7.80. The stock was down 0.63% on the session.
    • Elevation Oncology (NASDAQ:ELEV) stock broke to a new 52-week low of $3.20 on Wednesday. Shares of the company traded down 1.21%.
    • Miromatrix Medical (NASDAQ:MIRO) stock hit a yearly low of $3.50. The stock was down 6.17% for the day.
    • Better Therapeutics (NASDAQ:BTTX) stock achieved a new 52-week low on Wednesday morning, hitting $2.61 and moving down 4.63%.
    • CENTRAL & EASTERN EUROPE (NYSE:CEE) stock set a new 52-week low of $9.30 on Wednesday, moving down 14.19%.
    • Angion Biomedica (NASDAQ:ANGN) shares set a new 52-week low of $1.80. The stock traded down 4.0%.
    • First Trust/aberdeen (NYSE:FEO) shares made a new 52-week low of $11.36 on Wednesday. The stock was down 1.96% for the day.
    • Lixiang Education Holding (NASDAQ:LXEH) stock dropped to a yearly low on Wednesday of $4.05. Shares traded down 10.2%.
    • Applied Therapeutics (NASDAQ:APLT) stock broke to a new 52-week low of $1.81 on Wednesday. Shares of the company traded down 2.13%.
    • Femasys (NASDAQ:FEMY) shares moved down 3.01% on Wednesday to hit a new 52-week low of $2.52, drifting down 3.01%.
    • Cohen & Co (AMEX:COHN) shares set a new yearly low of $14.06 this morning. The stock was down 3.15% on the session.
    • Elite Education Gr Intl (NASDAQ:EEIQ) stock broke to a new 52-week low of $2.04 on Wednesday. Shares of the company traded down 8.26%.
    • Immix Biopharma (NASDAQ:IMMX) shares reached a new 52-week low of $2.72 on Wednesday morning, moving up 0.36%.
    • Eco Wave Power Global (NASDAQ:WAVE) stock achieved a new 52-week low on Wednesday morning, hitting $3.77 and moving down 12.67%.
    • Revelation Biosciences (NASDAQ:REVB) stock set a new 52-week low of $1.23 on Wednesday, moving down 7.52%.
    • InMed Pharmaceuticals (NASDAQ:INM) shares reached a new 52-week low of $0.85 on Wednesday morning, moving down 2.05%.
    • Nuwellis (NASDAQ:NUWE) shares hit a yearly low of $0.85. The stock was down 3.19% on the session.
    • Mobiquity Technologies (NASDAQ:MOBQ) shares moved down 2.44% on Wednesday to hit a new 52-week low of $1.20, drifting down 2.44%.

     

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $ADV
    $AGLE
    $AKA

    CompanyDatePrice TargetRatingAnalyst
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Hold
    Truist
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Neutral
    BofA Securities
    Certara Inc.
    $CERT
    2/27/2026$10.00Buy → Hold
    Craig Hallum
    Vital Farms Inc.
    $VITL
    2/27/2026$24.00Overweight → Equal-Weight
    Morgan Stanley
    GoodRx Holdings Inc.
    $GDRX
    2/27/2026Overweight → Neutral
    Analyst
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Sector Outperform → Sector Perform
    Scotiabank
    Duolingo Inc.
    $DUOL
    2/27/2026$95.00Overweight → Neutral
    Analyst
    Duolingo Inc.
    $DUOL
    2/27/2026$114.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vostrizansky Michael Warren bought $494,415 worth of shares (23,000 units at $21.50) (SEC Form 4)

    4 - Neptune Insurance Holdings Inc. (0002067129) (Issuer)

    2/24/26 6:36:04 PM ET
    $NP
    Specialty Insurers
    Finance

    $ADAP
    $ADV
    $AGLE
    $AKA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TYRVAYA issued to OYSTER POINT PHARMA INC

    Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form

    10/19/21 7:27:01 PM ET
    $OYST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certara to Participate in Upcoming Investor Conferences

    RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Date and Time: Tuesday, March 3rd, 2026, at 3:10PM ET Leerink Global Healthcare Conference Date and Time: Monday, March 9th, 2026, at 8:00AM ET Barclays 28th Annual Global Healthcare ConferenceDate and Time: Tuesday, March 10th, 2026, at 1:00PM ET Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 day

    2/27/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    1stDibs Reports Fourth Quarter and Full Year 2025 Financial Results

    1stdibs.com, Inc. (NASDAQ:DIBS), a leading online marketplace for luxury design products ("1stDibs" or the "Company"), today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Net revenue was $23.0 million, an increase of 1% year-over-year. Gross profit was $16.9 million, an increase of 3% year-over-year. Gross margin was 73.5%, compared to 72.3% in the fourth quarter 2024. GAAP net loss was $1.0 million compared to a net loss of $5.2 million in the fourth quarter 2024. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $1.3 million and 5.6%, respectively, compared to $(1.6) million and (7.2)%, r

    2/27/26 7:00:00 AM ET
    $DIBS
    Catalog/Specialty Distribution
    Consumer Discretionary

    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 346,200 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq List

    2/27/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Duolingo downgraded by Truist with a new price target

    Truist downgraded Duolingo from Buy to Hold and set a new price target of $100.00

    2/27/26 12:55:49 PM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Duolingo downgraded by BofA Securities with a new price target

    BofA Securities downgraded Duolingo from Buy to Neutral and set a new price target of $100.00

    2/27/26 10:22:22 AM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Certara downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00

    2/27/26 8:32:38 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $ADAP
    $ADV
    $AGLE
    $AKA
    SEC Filings

    View All

    SEC Form S-8 filed by Butterfly Network Inc.

    S-8 - Butterfly Network, Inc. (0001804176) (Filer)

    2/27/26 9:19:56 AM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form S-8 filed by 1stdibs.com Inc.

    S-8 - 1stdibs.com, Inc. (0001600641) (Filer)

    2/27/26 8:55:32 AM ET
    $DIBS
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-K filed by 1stdibs.com Inc.

    10-K - 1stdibs.com, Inc. (0001600641) (Filer)

    2/27/26 8:50:51 AM ET
    $DIBS
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Khajehnouri Nima

    3 - Dave Inc./DE (0001841408) (Issuer)

    2/26/26 10:59:52 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    President and CEO Aballi John sold $41,262 worth of shares (11,430 units at $3.61), decreasing direct ownership by 2% to 702,997 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    2/25/26 7:11:33 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Leadership Updates

    Live Leadership Updates

    View All

    Cohen & Company Announces Appointment of Pawel Skonieczka as Managing Director to Lead Coverage of Space Technology, Aerospace, & Communications Infrastructure in Capital Markets Segment

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- After nearly doubling deal flow and closing $43 billion in transactions in 2025, Cohen & Company Capital Markets ("CCM"), a division of Cohen & Company Securities, LLC, an indirect, controlled subsidiary of Cohen & Company Inc. (NYSE:COHN), announced the appointment of Pawel Skonieczka as a Managing Director to lead the expansion of the firm's advisory capabilities across Space Technology, Aerospace, and Communications Infrastructure. Mr. Skonieczka brings nearly two decades of experience advising public and private companies, financial sp

    2/26/26 10:43:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    BlackRock Appoints Citi to Provide Select ETF Middle Office Services on Aladdin

    Key Highlights: BlackRock has selected Citi to provide select middle office services for $4.0 trillion in U.S. domiciled iShares ETFs on the Aladdin platform1 This partnership enhances ETF order transparency and streamlines processing, reinforcing Citi's expanded ETF and middle office servicing capabilities The collaboration follows a 2021 mandate where Citi was appointed as an additional post-trade service provider for BlackRock's U.S. domiciled ETFs BlackRock has appointed Citi Investor Services to provide select middle office functions for $4.0 trillion in U.S. domiciled iShares ETFs on the Aladdin platform. Expanding on the long-standing partnership between BlackRock and C

    2/26/26 9:00:00 AM ET
    $C
    Major Banks
    Finance

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Financials

    Live finance-specific insights

    View All

    Dave to Report Fourth Quarter and Full Year 2025 Results and Participate in Upcoming Investor Conferences

    LOS ANGELES, CA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced its participation in two upcoming investor conferences following the Company's fourth quarter and full year 2025 earnings conference call on Monday, March 2, 2026, at 5:00 p.m. Eastern time. The earnings conference call and investor conference details are as follows: Earnings Conference Call Date: Monday, March 2, 2026Time: 5:00 p.m. Eastern timeConference Call Registration: linkWebcast: link The conference call will also be available for replay in the Events section of the Company's website, along with the transcript, at https://in

    2/26/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

    THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w

    2/26/26 8:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardagh Metal Packaging S.A. - Fourth Quarter and Full Year 2025 Results

    LUXEMBOURG, Feb. 26, 2026 /PRNewswire/ -- Ardagh Metal Packaging S.A. (NYSE:AMBP) today announced results for the fourth quarter and year ended December 31, 2025. December 31, 2025December 31, 2024ChangeConstant CurrencyFourth Quarter($'m except per share data)Revenue1,3461,19513 %10 %Loss for the period(16)(11)Adjusted EBITDA(1)1661641 %(1 %)Loss per share(0.03)(0.03)Adjusted earnings per share(1)0.030.03Dividend per ordinary share0.100.10Full YearRevenue5,4974,90812 %10 %Profit/(loss) for the year 11(3)Adjusted EBITDA (1)73967210 %8 %Loss per share (0.02)(0.05)Adjusted earning

    2/26/26 7:00:00 AM ET
    $AMBP
    Containers/Packaging
    Industrials

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Citigroup Inc.

    SC 13D - CITIGROUP INC (0000831001) ()

    1/5/94 12:00:00 AM ET
    $C
    Major Banks
    Finance

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary